Basic Information

Gene symbol CD19 Synonyms B4, CVID3 Type of gene protein-coding
Description CD19 molecule

GTO ID GTC0408
Trial ID NCT03391466
Disease Diffuse Large B-Cell Lymphoma
Altered gene CD19
Therapeutic/Target gene Target gene
TherapyCAR-T cell
Treatment YesCAR-Ta|Axicabtagene Ciloleucel|axi-cel
Generation2nd
PhasePhase3
Recruitment statusActive, Not Recruiting
TitleStudy of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)
Year2017
CountryUnited States
Company sponsorKite, A Gilead Company
Other ID(s)KTE-C19-107|2017-002261-22
Vector information
Vectorlentivirus
ConstructscFv-CD28-CD3ζ

Clinical Result

Cohort1: axi-cel
Administration route intravenous infusion
Dosage 2E6 cells/kg
Donor type Autologous
Pts 180
Age Adult, Older_Adult
Lymph depletion Yes
Outcome median event-free survival:(8.3 months; 95% CI, 4.5 to 15.8); 24 months free survival:41% (95% CI, 33 to 48)
Adverse reactions 91%(Grade 3 or higher adverse events); 6%(≥Grade 3 CRS); 21%(≥Grade 3 neurologic events)
References PMID: 34891224
Cohort2: standard-of-care
Administration route intravenous infusion
Donor type Autologous
Pts 179
Age Adult, Older_Adult
Lymph depletion Yes
Outcome median event-free survival:(2.0 months; 95% CI, 1.6 to 2.8); 24 months free survival:16% (95% CI, 11 to 22)
Adverse reactions 83%(Grade 4 or higher adverse events)
References PMID: 34891224

Relationship Graph

Overview of Knowledge Graph